Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Novel conditioning regimen for upfront haploidentical hematopoietic cell transplantation in children with severe aplastic anemia and donor-specific anti-HLA antibodies

Bone Marrow Transplantation volume 57, pages 304–305 (2022)Cite this article

Subjects

TO THE EDITOR:

Allogeneic hematopoietic cell transplantation (HCT) is curative for severe aplastic anemia (SAA) [1, 2]. For patients who lack an HLA-matched related donor, treatment options include immunosuppressive therapy (IST) using horse anti-thymocyte globulin (hATG) and cyclosporine (CsA) ±eltrombopag, HLA-matched unrelated donor, or alternative donor (haploidentical) HCT. Nevertheless, success of IST is about 60–70%, and from those 30–40% may eventually relapse [3]. Moreover, hATG and eltrombopag are not available in many centers and hence HCT becomes the sole curative option. However, in countries that lack national registry for unrelated donors, haploidentical HCT is the only available option for cure.

This is a preview of subscription content, access via your institution

Access options

References

  1. Ciceri F, Lupo-Stanghellini MT, Korthof ET. Haploidentical transplantation in patients with acquired aplastic anemia. Bone Marrow Transplant. 2013;48:183–5.

  2. Bacigalupo A. How I treat acquired aplastic anemia. Blood 2017;129:1428–36.

    Article  CAS  Google Scholar 

  3. Scheinberg P, Wu CO, Scheinberg P, Weinstein B, Nunez O, Sloand EM, et al. A randomized trial of horse versus rabbit antithymocyte globulin in severe acquired aplastic anemia. Blood. 2010;116:LBA – 4 – LBA – 4.

  4. Ciurea SO, Cao K, Fernadez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2018;53:521–34.

  5. Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129:30–7.

    Article  CAS  Google Scholar 

  6. Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLornan D, Raj K, et al. Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transpl. 2014;20:1711–6.

    Article  Google Scholar 

  7. Esteves I, Bonfim C, Pasquini R, Funke V, Pereira NF, Rocha V, et al. Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transpl. 2015;50:685–9.

    Article  CAS  Google Scholar 

  8. Bachegowda LS, Shah MV, Veltri LW, Tanase A, Popat U, Anderlini P, et al. HLA-mismatched bone marrow transplantation in severe aplastic anemia. Bone Marrow Transplant. 2017;52:1347–8.

  9. DeZern AE, Zahurak ML, Symons HJ, Cooke KR, Rosner GL, Gladstone DE, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020;4:1770–9.

    Article  CAS  Google Scholar 

  10. Yadav SP, Thakkar D, Chatterjee G, Kapoor R, Rastogi N. Upfront Haploidentical Stem Cell Transplant with Posttransplant Cyclophosphamide in Children with Severe Aplastic Anemia. J Pediatr Hematol Oncol. 2020;42:500.

    Article  Google Scholar 

  11. Dang BN, De Oliveira S, Gray A, Bowles LV, Moore TB. Successful engraftment of haploidentical bone marrow with post-transplantation cyclophosphamide in patients with aplastic anemia. Pediatr Transpl. 2020;24:1–5.

    Google Scholar 

  12. Iftikhar R, Chaudhry QN, Mahmood SK, Ghafoor T, Shahbaz N, Khan MA, et al. A novel TBI free conditioning protocol for haploidentical transplant in acquired aplastic anemia: (FluCAB-Prime). Bone Marrow Transplant. 2021;56:2309–11.

  13. Arcuri LJ, Nabhan SK, Cunha R, Nichele S, Ribeiro AAF, Fernandes JF, et al. Impact of CD34 cell dose and conditioning regimen on outcomes after haploidentical donor hematopoietic stem cell transplantation with post-transplantation cyclophophamide for relapsed/refractory severe aplastic anemia. Biol Blood Marrow Transpl. 2020;26:2311–7.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work required no support from any funding agency or pharmaceutical industry.

Author information

Authors and Affiliations

  1. Pediatric Hematology Oncology and Bone Marrow Transplantation, King Hussein Cancer Center, Amman, Jordan

    Hasan Hashem, Rawad Rihani, Mayada Abu Shanap, Eman Khattab & Iyad Sultan

  2. Department of Cellular Therapy and Applied Genomics, King Hussein Cancer Center, Amman, Jordan

    Abdelghani Tbakhi

Authors
  1. Hasan Hashem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rawad Rihani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mayada Abu Shanap
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eman Khattab
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Abdelghani Tbakhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Iyad Sultan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HH and IS collected, analyzed, and interpreted data and wrote the manuscript. HH, RR, MA, EK, and AT provided clinical information from patients and edited the manuscript. All the authors contributed to clinical care, and edited and approved the final manuscript.

Corresponding author

Correspondence to Hasan Hashem.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hashem, H., Rihani, R., Shanap, M.A. et al. Novel conditioning regimen for upfront haploidentical hematopoietic cell transplantation in children with severe aplastic anemia and donor-specific anti-HLA antibodies. Bone Marrow Transplant 57, 304–305 (2022). https://doi.org/10.1038/s41409-021-01536-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-021-01536-y

This article is cited by

Search

Advanced search

Quick links